Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REVANCE THERAPEUTICS, INC.

(RVNC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Revance Shares Slide After FDA Rejects DAXI Application

10/18/2021 | 04:26am EST

By Colin Kellaher

Shares of Revance Therapeutics Inc. tumbled in premarket trading Monday after the biotechnology company said the U.S. Food and Drug Administration had turned away its injection treatment for frown lines due to issues related to the drug's manufacturing plant.

The Newark, Calif., company late Friday said the FDA had issued a complete response letter, indicating that the agency wouldn't approve the application for DaxibotulinumtoxinA for Injection, or DAXI, in its current form.

Revance said the FDA indicated that it found deficiencies during its delayed inspection of its manufacturing plant in California, adding that the agency didn't identify any other issues.

Revance said it plans to request a meeting with the FDA as soon as possible to address the deficiencies, adding that it is "very disappointed by this unanticipated response."

Analysts at Mizuho said the latest development in the DAXI saga likely means a delay of about 12 to 15 months for approval of the drug.

The FDA in early 2020 had accepted Revance's application for DAXI, with a decision expected before the end of the year, but the agency later deferred its decision because it hadn't been able to inspect the manufacturing plant due to travel restrictions related to the Covid-19 pandemic. The FDA eventually conducted its pre-approval inspection in late June and early July of this year.

Revance shares fell sharply early last week after the FDA, responding to a Freedom of Information Act request, released a document outlining concerns raised by the inspection, but the stock rebounded Wednesday after Revance said it had already responded, and that it still expected FDA approval of DAXI by the end of this year.

Mizuho said it now assumes a late 2022 approval of the drug, with a launch in early 2023. The analysts cut their price target on Revance shares to $26 from $36 to reflect the delay, but they maintained their "buy" rating, saying they still expect DAXI will ultimately win FDA approval and represents a long-term opportunity.

Revance shares, which closed Friday at $22.71, were recently down nearly 32% to $15.47 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-18-21 0626ET

All news about REVANCE THERAPEUTICS, INC.
11/26ONGOING INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims ..
PR
11/19Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Ac..
BU
11/19Revance Therapeutics, Inc. to Present Clinical Data on Daxibotulinumtoxina for Injectio..
CI
11/18Revance to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
BU
11/17REVANCE ALERT : Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on..
BU
11/10Revance to Participate in the Stifel 2021 Virtual Healthcare Conference
BU
11/09Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update - Form ..
PU
11/09REVANCE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/09REVANCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Change in Dire..
AQ
11/09Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
More news
Analyst Recommendations on REVANCE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 74,8 M - -
Net income 2021 -288 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,00x
Yield 2021 -
Capitalization 921 M 921 M -
Capi. / Sales 2021 12,3x
Capi. / Sales 2022 7,75x
Nbr of Employees 470
Free-Float 96,9%
Chart REVANCE THERAPEUTICS, INC.
Duration : Period :
Revance Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REVANCE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 12,83 $
Average target price 28,10 $
Spread / Average Target 119%
EPS Revisions
Managers and Directors
Mark J. Foley Chief Executive Officer & Director
Dustin Sjuts President
Tobin C. Schilke Chief Financial Officer
Angus C. Russell Chairman
Abhay Joshi COO & President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REVANCE THERAPEUTICS, INC.-54.73%921
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678